NCT02319057

Pharmacokinetic Study of Single Doses of ORM-12741

Pharmacokinetic Study of Modified Release Formulations and an Immediate Release Formulation of ORM-12741 After Single Oral Doses

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Orion Corporation, Orion Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate ORM-12741 concentrations in the blood after different study drug formulations

Detailed description

The purpose of this study is to evaluate the pharmacokinetics and safety of single doses of modified release formulations and a immediate release formulation of ORM-12741

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ORM-12741 MR A	Modified release formulation of ORM-12741
DRUG	ORM-12741 IR	Immediate release formulation of ORM-12741
DRUG	ORM-12741 MR B	Modified release formulation of ORM-12741

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2014-12-18
• Last updated: 2015-05-06

Locations

1 site across 1 country: Finland